Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for pembrolizumab combined with chemotherapy or immunotherapy in non-small cell lung cancer (KEYNOTE-021) from phase 1/2 shows completed s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-12-02